Peptide therapy has become one of the more promising tools in functional and regenerative medicine – not as a trend, but as a way to address the biological mechanisms behind aging and chronic illness directly, rather than just managing symptoms.

The four compounds below represent some of the most compelling research in the clinical field right now. All four peptide compounds are available at Meeting Point Health, in Philadelphia, PA and are prescribed and administered under clinical supervision as part of our individualized treatment protocols.

Thymosin Alpha-1: Immune System Support

What is Thymosin Alpha-1? 

Thymosin Alpha-1 is a peptide naturally produced by the thymus gland, where much of the body’s immune education takes place.

How Does Thymosin Alpha-1 Work? 

As we age, thymic function declines, and with it, the immune system’s ability to mount precise, coordinated responses to infection and inflammation. Thymosin Alpha-1 helps restore that coordination by supporting the immune cells that identify threats, balancing the response between fighting active infection and managing inflammation, and strengthening the cells responsible for antiviral defense and clearing abnormal cells.

Who May Benefit From Thymosin Alpha-1? 

Thymosin Alpha-1 is most relevant for patients carrying a significant immune burden or chronic viral reactivation, autoimmune or inflammatory conditions, CIRS, or chronic Lyme. 

What to Expect if You Take Thymosin Alpha-1

Results tend to build gradually as underlying immune dysfunction improves. Patients typically report:

  • Fewer, milder infections: Reduced frequency and severity of illness as immune coordination improves.
  • Better recovery from chronic viral illness: Especially with Epstein-Barr Virus reactivation and similar viruses. 
  • More resilience with autoimmune conditions: As inflammation and immune imbalance ease.
  • Improved energy: As systemic inflammation decreases over the course of treatment.

Delivery Methods Available for Thymosin Alpha-1 

Thymosin Alpha-1 can be administered by IV or subcutaneous injection, depending on your specific protocol and clinical presentation. Your provider will determine which method best fits your treatment goals, other therapies you’re combining it with, and how your body responds over time. 

MOTS-c: Cellular Energy and Metabolism

What is MOTS-c? 

MOTS-c is a mitochondrial-derived peptide, meaning it’s encoded by mitochondrial DNA rather than the DNA in the cell nucleus. That makes it part of the body’s own internal signaling for energy regulation.

How Does MOTS-c Work?

MOTS-c helps muscle cells generate energy more efficiently while reducing the oxidative byproducts that damage tissue over time, one of the core drivers of aging and chronic disease. In short: more energy output, less cellular wear and tear.

Who May Benefit From MOTS-c?

MOTS-c is well-suited for patients experiencing metabolic dysfunction, chronic fatigue, or age-related decline in physical or cognitive performance, as well as those pursuing longevity optimization. To learn more about its metabolic applications, explore our blog: 2026 Trends in Regenerative Medicine.

What to Expect if You Take MOTS-c

After starting MOTS-c, many patients notice gradual improvements as cells become more efficient at producing and using energy. While results vary, you can typically expect:

  • Improved physical endurance: Increased stamina and exercise capacity.
  • More consistent energy: Steadier energy throughout the day.
  • Better metabolic function: Reduced metabolic resistance and more efficient energy use.
  • Improved body composition: Support for lean muscle and fat metabolism alongside healthy habits.
  • Sharper cognitive performance: Better focus and mental clarity as mitochondrial efficiency improves.

Delivery Methods Available for MOTS-c 

MOTS-c is administered by IV or subcutaneous injection. Your provider will recommend a delivery method based on your metabolic goals, whether you’re combining it with other peptides or therapies, and what fits best with your overall treatment plan.

LL-37: Broad-Spectrum Infection Defense

What is LL-37?

LL-37 is the body’s only known member of the cathelicidin family, a class of antimicrobial peptides the immune system produces as a first line of defense.

How Does LL-37 Work

LL-37 physically disrupts bacterial cell membranes, inhibits fungal growth, and interferes with viral replication, making it simultaneously antibacterial, antiviral, and antifungal. This breadth is unusual and valuable for patients dealing with layered or chronic infections where single-target treatments fall short. Beyond infection, LL-37 supports wound healing and tissue repair, calms gut inflammation, and is being studied for its role in cancer immunity.

Who May Benefit From LL-37?

LL-37 is particularly valuable for patients dealing with chronic or recurrent infections, mold toxicity, and biotoxin exposure, as well as those with GI inflammation or in cancer support protocols.

What to Expect if You Take LL-37

As LL-37 begins supporting your body’s immune response and natural repair processes, many patients notice gradual improvements over the course of treatment. Results vary, but potential benefits include:

  • Enhanced immune support: Improved resilience against recurrent infections.
  • Accelerated tissue repair: Faster healing of wounds and damaged tissue.
  • Improved digestive health: Reduced gastrointestinal inflammation.
  • Decreased systemic inflammation: Especially for those recovering from mold or biotoxin exposure.

Delivery Methods Available for LL-37

LL-37 is administered by IV or subcutaneous injection. Your provider will help determine the right method based on the complexity of your infectious burden, any co-occurring conditions, and how your protocol is structured alongside other treatments.

FOXO4-DRI: Clearing Aged Cells

What is FOXO4-DRI?

 FOXO4-DRI belongs to a category of compounds called senolytics, a relatively new class of therapeutics designed to selectively target and eliminate senescent cells: cells that have stopped dividing but haven’t died, and that release inflammatory signals damaging the tissue around them.

How Does FOXO4-DRI Work?

FOXO4-DRI was developed to overcome the resistance senescent cells have to normal cell death. It works by disrupting the interaction these cells depend on to survive, reactivating their internal death pathway while leaving healthy cells unaffected. Early research shows this can meaningfully improve blood vessel function by clearing senescent cells that line the vessels.

Who May Benefit From FOXO4-DRI? 

FOXO4-DRI is most relevant for patients focused on longevity, vascular health, and addressing the accumulated cellular burden of aging or chronic illness. Worth noting: FOXO4-DRI is earlier in its research timeline than the other peptides here. The mechanism is well understood and early data is encouraging, but long-term human studies are still limited. At Meeting Point Health, we prescribe it thoughtfully, in patients for whom the clinical rationale is clear and who understand the current state of the evidence.

What to Expect if You Take FOXO4-DRI

Because FOXO4-DRI works by gradually reducing the body’s senescent cell burden, results tend to build over time rather than appear quickly. While every patient’s experience is unique, patients typically report:

  • Increased energy levels: Greater day-to-day vitality as cellular function improves.
  • Reduced systemic inflammation: A gradual decline in chronic inflammation.
  • Improved vascular health: Enhanced circulation and blood vessel function.
  • Greater physical resilience: Improved recovery, mobility, and ability to stay active.

Delivery Methods Available for FOXO4-DRI

When it comes to receiving FOXO4-DRI, intravenous delivery is the method used. This allows for precise, controlled dosing given the compound’s earlier stage of clinical development.

Clinical Oversight Matters

These are prescription peptides with real physiological effects; these are not supplements. Dosing, delivery, and protocol design require clinical judgment, which is why we caution strongly against sourcing any of these compounds from unregulated online sources. Those products aren’t manufactured for human use and carry real risk.

At Meeting Point Health, every peptide protocol starts with a full evaluation of your history, labs, and clinical picture. We source exclusively from vetted compounding pharmacies. If you’re curious whether peptide therapy fits your health goals, click to schedule a discovery call. 

Helpful Links:

Related Reading:

Frequently Asked Questions

Are these peptides safe? Several of these are newer compounds, and long-term human trials are still limited for some. What we have is a growing body of research and real-world clinical experience. Every protocol here starts with a thorough evaluation of your health history.

Do I need a prescription for peptide therapy? Yes. All peptides used at Meeting Point Health are prescribed and administered under clinical supervision. We strongly advise against sourcing peptides from unregulated online sellers.

Can these peptides be combined with other treatments? Often, yes. Peptides tend to work best as part of a broader protocol addressing multiple systems at once. The right combination depends on your individual presentation.

How do I know which peptide is right for me? There’s no one-size-fits-all answer. A comprehensive consultation lets us assess your labs, symptoms, and history to determine which compounds, if any, make sense for you.

References

Gu, B., Zhou, Y., Nie, Y., Wang, L., Liang, L., Liao, Z., Wen, J., Guan, X., Chen, M., Wu, J., & Pei, F. (2025). Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials. Frontiers in cellular and infection microbiology, 15, 1673959. https://doi.org/10.3389/fcimb.2025.1673959 

Gudiksen, A., Hansen, C. C., van der Stede, T., Daugaard, A. H., Schmidt, J. H., Ringholm, S., Merimi, M., Al-Obaidi, F. R., Kristoffersen, A. T., Zole, E., Regenberg, B., Kjøbsted, R., Wojtaszewski, J., Hellsten, Y., & Pilegaard, H. (2026). MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner. Free radical biology & medicine, 246, 682–696. 

Hu, Z., Li, F., Hu, C., Shan, Q., Tang, Z., Jiang, M., Yi, X., Chen, X., Jin, L., Wang, X., & Wang, Y. (2026). FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway. Frontiers in bioengineering and biotechnology, 13, 1729166. https://doi.org/10.3389/fbioe.2025.1729166

Keshri, A. K., Rawat, S. S., Chaudhary, A., Sharma, S., Kapoor, A., Mehra, P., Kaur, R., Mishra, A., & Prasad, A. (2025). LL-37, the master antimicrobial peptide, its multifaceted role from combating infections to cancer immunity. International journal of antimicrobial agents, 65(1), 107398. https://doi.org/10.1016/j.ijantimicag.2024.107398